HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,547,134 | -19.6% | 328,459 | -24.1% | 1.70% | -11.0% |
| Q2 2023 | $15,614,018 | -4.6% | 432,881 | +1.0% | 1.91% | -8.8% |
| Q1 2023 | $16,367,088 | -34.9% | 428,570 | -3.0% | 2.09% | -37.9% |
| Q4 2022 | $25,138,932 | +42.5% | 441,809 | -1.0% | 3.37% | +42.0% |
| Q3 2022 | $17,637,000 | -26.8% | 446,049 | -18.5% | 2.37% | -11.4% |
| Q2 2022 | $24,085,000 | +65.6% | 547,381 | +50.1% | 2.68% | +94.3% |
| Q1 2022 | $14,545,000 | -1.4% | 364,718 | -0.6% | 1.38% | +18.3% |
| Q4 2021 | $14,753,000 | -41.5% | 366,897 | -40.8% | 1.16% | -44.7% |
| Q3 2021 | $25,212,000 | +3.1% | 619,766 | +15.1% | 2.11% | +6.8% |
| Q2 2021 | $24,460,000 | +8.1% | 538,656 | -0.8% | 1.97% | -0.8% |
| Q1 2021 | $22,628,000 | -16.1% | 542,764 | -14.1% | 1.99% | -13.5% |
| Q4 2020 | $26,984,000 | +71.9% | 631,807 | +5.7% | 2.30% | +73.4% |
| Q3 2020 | $15,702,000 | +31.3% | 597,477 | +33.9% | 1.32% | +25.3% |
| Q2 2020 | $11,959,000 | – | 446,070 | – | 1.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |